Abstract:There is a clinical need to develop lipid nanoparticles (LNPs) to deliver congenital therapies to the fetus during pregnancy. The aim of these therapies is to restore normal fetal development and prevent irreversible conditions after birth. As a first step, LNPs need to be optimized for transplacental transport, safety on the placental barrier and fetal organs and transfection efficiency. We developed and characterized a library of LNPs of varying compositions and used machine learning (ML) models to delineate the determinants of LNP size and zeta potential. Utilizing different in vitro placental models with the help of a Random Forest algorithm, we could identify the top features driving percentage LNP transport and kinetics at 24 h, out of a total of 18 input features represented by 41 LNP formulations and 48 different transport experiments. We further evaluated the LNPs for safety, placental cell uptake, transfection efficiency in placental trophoblasts and fetal lung fibroblasts. To ensure the integrity of the LNPs following transplacental transport, we screened LNPs for transport and transfection using a high-throughput integrated transport-transfection in vitro model. Finally, we assessed toxicity of the LNPs in a tracheal occlusion fetal lung explant model. LNPs showed little to no toxicity to fetal and placental cells. Immunoglobin G (IgG) orientation on the surface of LNPs, PEGylated lipids, and ionizable lipids had significant effects on placental transport. The Random Forest algorithm identified the top features driving LNPs placental transport percentage and kinetics. Zeta potential emerged in the top driving features. Building on the ML model results, we developed new LNP formulations to further optimize the transport leading to 622 % increase in transport at 24 h versus control LNP formulation. To induce preferential siRNA transfection of fetal lung, we further optimized cationic lipid percentage and the lipid-to-siRNA ratio. Studying LNPs in an integrated placental and fetal lung fibroblasts model showed a strong correlation between zeta potential and fetal lung transfection. Finally, we assessed the toxicity of LNPs in a tracheal occlusion lung explant model. The optimized formulations appeared to be safe on ex vivo fetal lungs as indicated by insignificant changes in apoptosis (Caspase-3) and proliferation (Ki67) markers. In conclusion, we have optimized an LNP formulation that is safe, with high transplacental transport and preferential transfection in fetal lung cells. Our research findings represent an important step toward establishing the safety and effectiveness of LNPs for gene delivery to the fetal organs.

Placenta-specific gene manipulation using lentiviral vector and its application

Advance in Placenta Drug Delivery: Concern for Placenta-Originated Disease Therapy.

Size-dependent Placental Retention Effect of Liposomes in ICR Pregnant Mice: Potential Superiority in Placenta-Derived Disease Therapy

In vivo investigation of ruminant placenta function and physiology-a review

Generating Functional Multicellular Organoids from Human Placenta Villi

Use of transgenic mice model for understanding the placentation: towards clinical applications in human obstetrical pathologies?

Identifying novel regulators of placental development using time-series transcriptome data

Small Non-Coding RNAs Transfer Through Mammalian Placenta and Directly Regulate Fetal Gene Expression

Identifying novel regulators of placental development using time series transcriptomic data and network analyses

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

Placental Therapeutic Targets and Nanodelivery Systems

Single‐cell and Spatial Transcriptomics: Discovery of Human Placental Development and Disease

A spatiotemporal transcriptomic atlas of mouse placentation

Genome-wide identification of transcriptional enhancers During human placental development and association with function, differentiation, and disease

Optimizing lipid nanoparticles for fetal gene delivery in vitro, ex vivo, and aided with machine learning

Dynamic Proteomic Profiles of in Vivo- and in Vitro-Produced Mouse Postimplantation Extraembryonic Tissues and Placentas

Nanotechnological approaches for the treatment of placental dysfunction: recent trends and future perspectives

Plac1 Expression Pattern at the Mouse Fetomaternal Interface and Involvement in Trophoblast Differentiation

New era of trophoblast research: integrating morphological and molecular approaches

Longitudinal intravital imaging of mouse placenta

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications